Use of Teplizumab to Modulate Stage 2 Type 1 Diabetes in Two Individuals With Autoimmune Polyendocrine Syndrome 1.

Journal:

Diabetes Care

Published:

2025-11-13

DOI:

10.2337/dc25-1444

Affiliations:

11

Authors:

16

Go to article

Institutions	Authors	Share
Vanderbilt University Medical Center (VUMC), United States of America (USA)	8.000000	0.50
NIH National Institute of Allergy and Infectious Diseases (NIAID), United States of America (USA)	3.000000	0.19
University of Florida (UF), United States of America (USA)	2.000000	0.13
University of Tennessee Health Science Center (UTHSC), United States of America (USA)	2.000000	0.13
The University of Texas at Austin (UT Austin), United States of America (USA)	1.000000	0.06

Interested in Immunology?